Enzyme could be major driver of preeclampsia
Finding could lead to new treatments for life-threatening pregnancy complication
DALLAS – Sept. 8, 2021 – A new study by UT Southwestern scientists indicates that an enzyme called protein phosphatase 2 (PP2A) appears to be a major driver of preeclampsia, a dangerous pregnancy complication characterized by the development of high blood pressure and excess protein in the urine. The finding, published in Circulation Research, could lead to new treatments for preeclampsia other than premature delivery, which is often the only option.
“Preeclampsia is a regrettably common cause of premature birth, which can be life-threatening for babies and lead to lifelong consequences. Through identifying PP2A’s role in this condition, we may be able to develop treatments for preeclampsia that are far better for both mothers and babies,” said study leader Philip W. Shaul, M.D., Professor and Vice Chair for Research in the Department of Pediatrics at UTSW and Director of the Center for Pulmonary and Vascular Biology. Dr. Shaul co-led this study with Chieko Mineo, Ph.D., Professor of Pediatrics and Cell Biology.
Preeclampsia, which affects 5 to 7% of pregnant women worldwide, can be deadly for gestating mothers and their babies and requires delivery at a premature stage.
Although the causes of preeclampsia aren’t well understood, explained Dr. Shaul, researchers have linked the condition to a variety of risk factors. One is an autoimmune disease known as antiphospholipid syndrome (APS), in which antibodies react to proteins on the surface of some cells. Although APS is relatively rare, affecting only about 5 in every 100,000 people, studies have identified APS antibodies in about 29% of pregnant women with preeclampsia.
To better understand how APS leads to preeclampsia, Dr. Shaul, Dr. Mineo, and their colleagues created an animal model by injecting pregnant mice with APS antibodies. These animals developed high blood pressure and a rise in urine protein, which are characteristics of preeclampsia. In contrast, the APS antibodies didn’t affect blood pressure in nonpregnant mice.
Based on previous work, the researchers knew that a protein called ApoER2 may be related to the harmful actions of APS antibodies on placental cells called trophoblasts. These cells, which normally journey from the fetal side of the placenta to the maternal side to provide the fetus with nutrients, don’t successfully make that connection in preeclampsia. In mice, the APS antibodies prevented trophoblast migration, and growth of the fetus was restricted. When the researchers genetically engineered mice without ApoER2 in trophoblasts, the fetuses developed normally despite APS antibody treatment, and the mothers were protected from developing preeclampsia.
But the scientists knew that ApoER2 didn’t tell the whole story. They found that in the presence of the APS antibodies, ApoER2 triggers the activity of PP2A, an enzyme that regulates protein functions throughout the body. Further experiments showed that in the pregnant mice with APS antibodies, heightened activity in PP2A increased trophoblast production of proteins known to be involved in preeclampsia.
When the researchers gave the pregnant mice a drug that inhibits PP2A, they were protected from preeclampsia, and the treatment had no apparent harmful effects on the mice or their gestating babies.
Hoping to translate these findings to human patients, the scientists examined placentas from women with APS, finding that they too had increased activity of PP2A. However, in a surprising turn, they discovered that compared with placentas from normal pregnancies, those from preeclamptic patients without APS also had increased PP2A activity, suggesting that this mechanism could be operating in a variety of forms of preeclampsia. With further research, Dr. Shaul said, treatments targeting PP2A or its related machinery in the trophoblast may eventually be viable treatments for preeclampsia in pregnant women.
Other UTSW researchers who contributed to this study include Haiyan Chu, Anastasia Sacharidou, An Nguyen, Chun Li, Ken L. Chambliss, Yu-Min Paul Shen, Julie Lo, Joachim Herz, Denise K. Marciano, Alina P. Montalbano, Xue Xiao, and Lin Xu.
This work was supported by grants from the National Institutes of Health (T32HL098040, R01HL109604, R01HD 094365, R01HL118001, R01HL147403, R37HL63762, R01NS093382, NS108115, RF1AG053391, 5R01HD100179-02), the Canadian Institutes of Health Research (201203MOP-275374-CIA-CBBA-109624, the American Heart Association/the Harry S. Moss Heart Trust Postdoctoral Fellowship (18POST33960170), the BrightFocus Foundation, the Bluefield Project, Harrington Scholar-Innovator Award, the Hartwell Foundation, the Crystal Charity Ball Center for Pediatric Critical Care Research, and the Children's Medical Center Foundation.
Dr. Herz holds the Presbyterian Village North Foundation Distinguished Chair in Alzheimer’s Disease Therapeutic Research and the Thomas O. and Cinda Hicks Family Distinguished Chair in Alzheimer’s Disease Research. Dr. Marciano holds the Carolyn R. Bacon Distinguished Professorship in Medical Science and Education. Dr. Shaul holds the Associates First Capital Corporation Distinguished Chair in Pediatrics.
About UT Southwestern Medical Center
UT Southwestern, one of the nation’s premier academic medical centers, integrates pioneering biomedical research with exceptional clinical care and education. The institution’s faculty has received six Nobel Prizes, and includes 25 members of the National Academy of Sciences, 16 members of the National Academy of Medicine, and 13 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,800 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide care in about 80 specialties to more than 117,000 hospitalized patients, more than 360,000 emergency room cases, and oversee nearly 3 million outpatient visits a year.